| Species |
Human |
| Protein Construction |
LAG3/CD223 (Leu23-Leu450)_x000D_
Accession # P18627-1 |
hFc |
| N-term |
C-term |
|
| Purity |
> 95% as determined by Bis-Tris PAGE |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized Human FGL1, His Tag at 1μg/ml (100μl/well) on the plate can bind LAG3/CD223 hFc Chimera, Human. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
72.4 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 75-80 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
LAG-3, is a protein which in humans is encoded by the LAG3 gene, which is a cell surface molecule with diverse biologic effects on T cell function. It is an immune checkpoint receptor and as such is the target of various drug development programs by pharmaceutical companies seeking to develop new treatments for cancer and autoimmune disorders. |
| Synonyms |
CD223; FDC; LAG3; LAG-3; sLAG-3 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
